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Introduction: Cytogenetics at diagnosis is themost powerful
prognostic factor in acute lymphoblastic leukemia (ALL) pa-
tients treated with conventional chemotherapy. However,
less is known about the prognostic signiﬁcance of initial
cytogenetics on patients who undergo allogeneic hemato-
poietic stem cell transplantation (alloHCT).
Methods: The objective was to investigate the effect of cy-
togenetics, and other disease-/transplant-related factors, on
leukemia-free survival (LFS), overall survival (OS), relapse
incidence (RR) and non-relapse mortality (NRM) among
adult ALL patients who undergo alloHCT. We retrospectively
analyzed a consecutive case-series of 359 adult ALL alloHCT
patients treated at the City of Hope from 09/2003 to 03/2014
(analytic date: 08/2014). Univariate Cox regression analyses
(or competing risks analogue) were performed evaluating
age at alloHCT, cytogenetic risk, leukemia phenotype (B vs.
T), initial WBC count, disease status at alloHCT, stem cell
source, conditioning intensity, donor type, and GVHD pro-
phylaxis (tacrolimus/sirolimus T/S-based vs. others). Signif-
icant factors (p<0.10) by univariate analysis were included in
the multivariable model.
Results: The median age was 38 years (range: 18-72). The
majority of patients (n¼325; 91%) were B-cell, median WBC
at diagnosis was 17x103/mL. Cytogenetic risk at diagnosis
was classiﬁed as good, intermediate, poor or unknown in 2%,
43%, 46% and 9%, respectively. Median time from diagnosis to
alloHCT was 7 months (range: 2.2-279.1). Disease status at
alloHCT was CR1, CR2 and >CR2/refractory in 60%, 17% and
23% of cases, respectively. The source of stem cells was pe-
ripheral blood in 308 patients (86%). Donors were matched
siblings in 193 patients (54%); conditioning regimen was
myeloablative in 81%. T/S-based GVHD prophylaxis was used
in 289 patients (81%). Median follow-up: 45 months (range:
3-128) in surviving patients; 3-year OS, LFS and RR estimates
were 54%, 47% and 27%, respectively; one-year NRMwas 19%.
By univariate analysis, cytogenetic risk, disease status at
alloHCT, stem cell source and T/S usagewere predictive for OS
andLFS. Inmultivariable analyses, disease status atHCTandT/
S usagewere independent predictors for LFS [CR1 vs. CR2: HR
¼ 1.69, p ¼ 0.02; CR1 vs. others: HR ¼ 2.94, p < 0.01; T/S vs.
others: HR ¼1.5, p ¼ 0.03] and OS [CR1 vs. CR2: HR ¼ 1.89, p
<0.01; CR1 vs. others: HR ¼ 2.82, p < 0.01; T/S vs. others: HR
¼1.53, p¼ 0.04].For RR, only disease status at HCT was found
to be predictive [CR1 vs. CR2: HR ¼ 2.17, p <0.01; CR1 vs.
others: HR ¼ 3.48, p<0.01]. Only T/S usage was associated
with reduced NRM [T/S vs. others: HR ¼1.7, p ¼ 0.04].
Conclusions: Among adult ALL patients who underwent
alloHCT, cytogenetics at diagnosis did not inﬂuence out-
comes. However, non-CR1 status at HCT adversely affected
OS, LFS and LR. Usage T/S based GVHD prophylaxis regimen
was associated with improved OS, LFS and NRM.71
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Background: Central nervous system (CNS) is the most
common extramedullary site involved in acute lympho-
blastic leukemia (ALL) at diagnosis and at the time of relapse.
Although some studies have shown an adverse impact of CNS
involvement on ALL outcomes when treated with chemo-
radiotherapy, limited data is available on the prognostic
implication of CNS involvement in patients who undergo
AlloHCT. The objective of our study was to analyze charac-
teristics and outcomes of patients with ALL and history of
CNS involvement who had undergone AlloHCT.
Methods: We reviewed all consecutive patients with ALL
who had undergone AlloHCT between October 2004 and
December 2013 at City of Hope and identiﬁed cases with
history of CNS involvement either at diagnosis or CNS relapse
[isolated or combined CNS and bone marrow (BM)] prior to
AlloHCT. Patient characteristics and outcomes were collected
and analyzed.
Results: Among 436 patients transplanted during the
selected period, 56 (13%) had history of CNS involvement
prior to AlloHCT. Of those patients with prior CNS
involvement, 11 (20%) had CNS disease at presentation, 25
(44%) had isolated CNS relapse, and 20 (36%) had com-
bined CNS/BM relapse. Median age for eligible patients
was 25.5 (range¼2.4-61.4). Poor risk cytogenetics were
identiﬁed in 22 (40%) of patients. Donor was sibling in 24
patients (43%) and graft source was peripheral blood in 34
(61%) patients. Disease status at transplant was CR1 in 11
patients (20%), CR2 in 31 patients (55%), and advanced/
refractory disease in 14 patients (25%). The conditioning
regimen was myeloablative in 42 (75%), and TBI-based in
40 (71%) patients.
With overall median follow-up of 13.5 months
(range¼0.3-112.8), 1- and 2-year EFS were 49.8% and 42.3%,
while 1- and 2-year OS were 57 and 45%, respectively. Day
100 and 1-year non-relapse mortality were 10.7% and 23%,
and 1- and 2-year relapse rate were 27% and 30%, respec-
tively. Only 6 patients (10%) relapsed post AlloHCT with CNS
disease. Patients with CNS disease at presentation as well as
combined CNS/BM relapse had inferior outcomes compared
to those with isolated CNS relapse prior to transplant (2-year
OS 32.7 and 33.7 vs. 72%, respectively. p¼0.0123). In uni-
variate analysis, among all factors examined, age was the
only signiﬁcant factor for OS [pediatric vs. adult: HR¼ 2.44
(CI: 1.06-5.62); p ¼ 0.04]. In multivariate analysis, age was
independent factor for both OS [pediatric vs. adult: HR¼ 2.67
(CI: 1.03-6.95), p ¼ 0.04] and relapse [pediatric vs. adult: HR
¼ 4.57 (CI: 1.04-20.07), p ¼ 0.05]. WBC on presentation was
independent factor for only relapse [more vs. less than 30K:
HR ¼ 3.53 (CI: 1.02-12.21), p ¼ 0.04].
Conclusions: AlloHCT is effective in treating ALL with CNS
involvement and post-transplant CNS relapse is uncommon.
Table
Characteristic N[67 (%)
Male 49 (73)
Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107S80Patients who undergo AlloHCT with isolated CNS relapse
have superior outcome compared to those with combined
CNS and BM relapse or CNS involvement at diagnosis.Female 18 (27)
Age at Transplant
</30 31 (46)
>30 36 (54)
WBC at Diagnosis (x109/L)
<100 40 (60)
>100 8 (12)
Unknown 19 (28)
Extramedullary Disease at Dx
Yes 37 (55)
No 31 (45)
CNS Disease
Yes 8 (17)
No 5 (87)
Unk 1 (6)
Cytogenetics (SWOG)
Intermediate 37 (55)
High 2 (3)
Very High 4 (6)
BCR-ABL 2 (3)
Unknown 22 (33)
Disease Status at Transplant
CR1 21 (31)
CR2+ 31 (46)
NR/PD 15 (22)
Donor Source
Unrelated 29 (43)
Sibling 35 (52)
Parent 3 (5)
Stem Cell Source
BM 18 (27)
PBSC 42 (63)
CB 7 (10)
TBI 22 (33)
No TBI 45 (67)
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Introduction: T-ALL represents 20-25% of all cases of ALL,
with cure rates of 40% with chemotherapy alone. Allo-SCT
can improve survival in ﬁrst remission (CR1), and is the only
curative therapy for patients with relapsed or refractory
disease. We performed a review of all cases of T-ALL treated
with Allo-SCT at MDACC with the aim of identifying prog-
nostic markers to improve outcomes.
Methods: All patients who received ﬁrst allo-SCT for T-ALL
between 2000-2014were analyzed. Overall survival (OS) and
progression free survival (PFS) were estimated using the
Kaplan-Meier method. Cumulative incidence (CI) of relapse
(CIR), acute GVHD (aGVHD), and chronic GVHD (cGVHD)
were determined utilizing the cumulative incidence method
to account for competing risks. Given that disease relapse
was the primary cause of treatment failure, we evaluated
prognostic factors for relapse using Cox Proportional Haz-
ards regression analysis on univariate and multivariate
analysis.
Results: 67 patients received ﬁrst allo-SCT, with a median
age of 31 years (range 2-70), and a median follow-up time
among survivors of 35 months. 93% of patients received
myeloablative (MA) conditioning, with primarilytacroli-
mus/methotrexate +/- ATG GVHD prophylaxis (Table) The
3-year OS estimate was 34%, and 3-year PFS was 32%. In
patients transplanted in CR1, the OS was 57%, in CR2+,
30%, and in no-response/progressive disease (NR/PD) was
13%. The 3-year CIR was 54%, CI NRM 10% and CI cGVHD
23%. 100-day CIR II-IV aGVHD was 42%. On multivariate
analysis, male sex (HR 2.4, p¼0.055), and PD/NR (HR 2.9,
p¼0.003) were the only signiﬁcant predictors of relapse.
Minimal residual disease (MRD) by ﬂow cytometry at
transplant was predictive for relapse (HR 2.5, p¼0.03) on
univariate, but could not be analyzed on multivariate
analysis due to low numbers (n¼10), though 8/10 patients
died of relapse. CR1 vs CR2 on univariate was borderline
signiﬁcant (HR 3.96, p¼0.06). T-Cell subtyping will be
available at the time of presentation.
Conclusion:We present the largest single institutional study
of patients with T-ALL to date. Relapsewas themajor cause of
death in this cohort, with male sex and resistance to
chemotherapy as independent predictors of progression,
while transplant in CR1 trended to be advantageous for OS.
Novel strategies to decreaseMRD and relapse post transplant
are needed to improve outcomes.73
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